Results 261 to 270 of about 13,616,352 (396)

The contribution of extracellular RNA and its derived biomaterials in disease management

open access: yesBMEMat, EarlyView.
The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei   +8 more
wiley   +1 more source

Unveiling the complexity of cellular senescence in cancers: From mechanism to therapeutic opportunities

open access: yesBMEMat, EarlyView.
This review highlights the complex roles of cellular senescence in cancer progression and suppression, discusses the mechanisms and regulatory pathways involved, and evaluates the efficacy of the “One‐Two punch” sequential treatment approach while addressing emerging challenges in this novel therapeutic strategy.
Qiuming Pan   +12 more
wiley   +1 more source

CDK activity at the centrosome regulates the cell cycle

open access: yesCell Reports
Summary: In human cells and yeast, an intact “hydrophobic patch” substrate docking site is needed for mitotic cyclin centrosomal localization. A hydrophobic patch mutant (HPM) of the fission yeast mitotic cyclin Cdc13 cannot enter mitosis, but whether ...
Emma L. Roberts   +5 more
doaj  

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

open access: yesCancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang   +18 more
wiley   +1 more source

A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

open access: yesCancer Communications, EarlyView.
Abstract Background The combined use of anti‐programmed cell death protein 1 (PD‐1)/anti‐cytotoxic T‐lymphocyte associated protein 4 (CTLA‐4) checkpoint inhibitors has been effective in various cancer types. The Southwest Oncology Group (SWOG) Dual Anti‐CTLA‐4 and Anti‐PD‐1 Blockade in Rare Tumors (DART) S1609 study investigated ipilimumab and ...
Young Kwang Chae   +16 more
wiley   +1 more source

A critical balance between Cyclin B synthesis and Myt1 activity controls meiosis entry in Xenopus oocytes

open access: yesDevelopment, 2011
M. Gaffré   +6 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy